Zimbabwe has rejected a major American health deal worth $367m (272 million pounds) over five years because of Washington's request for confidential information.
This move was revealed following a government memo from December was disclosed, which showed President Emmerson Mnangagwa deemed the agreement was "lopsided".
An official spokesperson later clarified that the US was requesting genetic material for scientific study and commercial purposes but was unwilling to share the benefits from future medical innovations.
"We will now turn to the difficult and regrettable process of ending our health aid in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for continued talks to secure a deal suitable to both sides so the nation's critical HIV treatment initiative can be sustained.
Broader Implications
This development follows a similar situation in Kenya, where a court blocked a related deal with the US following concerns were raised about the safety of Kenyans' medical information.
Since returning to office last year, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing direct bilateral agreements to enhance openness and responsibility.
According to statements, Sixteen nations in Africa have so far signed similar health pacts, constituting over $18.3bn in new funding.
Specifics of the Rejected Agreement
The money for Zimbabwe was intended to supported "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this partnership could have provided significant advantages for the people of Zimbabwe, especially the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to surrender its biological resources and data over an extended period, without any corresponding promise of benefiting from any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," Mangwana explained.
"Effectively, our country would provide the raw materials for scientific discovery without any certainty that the end products would be accessible to our population if a future disease outbreak arise."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its pursuit of one-on-one deals were disrupting systems previously set up via the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage potential global health emergencies.
"This framework is intended to guarantee that when a country contributes its samples, the benefits – including medicines and cures – are shared equitably, not monopolised exclusively by those with the funds to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," he added.
"We are open to further dialogue with our American counterparts on how future co-operation could be designed in a manner that honours the independence and dignity of both nations."
Medical Community Response
A leading public health body expressed it understood the official position, but recommended that negotiations need to persist considering much of the country's Aids initiatives depended on foreign aid.
"In cases where technical issues arise, such as those relating to information security or agreement terms, these can often be addressed via technical clarification and mutually agreed protections," the group added.
This impasse emphasises the complex tensions between receiving crucial international aid and safeguarding national sovereignty in an ever more data-driven world.